CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 102 enrolled
Drug / intervention
corifollitropin alfa +7 moredrug
Likely dose
corifollitropin alfa 100 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00702546
NCT00702546N/ACompleted
CompareCT.gov

Follow-up Protocol to Collect the Outcome of Frozen-thawed Embryo Transfer Cycles After Cryopreservation of Embryos in Clinical Trial 107012

Organon and Co·observational·Posted Jun 20, 2008·Updated Feb 3, 2022

In Brief

An observational study evaluating corifollitropin alfa, recFSH (follitropin alfa), and 6 other interventions for In Vitro Fertilization. Completed, enrolled 102 participants.

Detailed Summary

Clinical trial objective is to collect the outcome of Frozen-Thawed Embryo Transfer (FTET) cycles performed after the embryos are cryopreserved in the base study P05690 in order to estimate the cumulative pregnancy rate for each treatment group.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIn Vitro Fertilization
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 20, 2008
Enrollment StartDec 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.0 years ago

Interventions

corifollitropin alfadrug

Single injection of 100 μg corifollitropin alfa administered under protocol P05690

recFSH (follitropin alfa)biological

Daily recFSH administered under protocol P05690

gonadatropin releasing hormone (GnRH) antagonist ganirelixdrug

GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690

human chorion gonadatropin (hCG)drug

hCG 5,000 IU or 10,000 IU administered SC under protocol P05690

progesteronebiological

Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.

placebo-recFSH (follitropin alfa)drug

Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690

placebo-corifollitropin alfadrug

Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690

open-label recFSHbiological

Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590